HomeNewsBusinessCNBC-TV18 CommentsGSK's Andrew Witty not a fan of universal drug pricing
Trending Topics
Sensex Live
Meesho IPO GMP
Exato Technologies IPO Allotment
Aequs IPO GMP
Vidya Wires IPO

GSK's Andrew Witty not a fan of universal drug pricing

He has the reputation of being perhaps the most outspoken CEO among the big pharma companies.

September 28, 2011 / 09:19 IST
Story continues below Advertisement
Remove Ad

He has the reputation of being perhaps the most outspoken CEO among the big pharma companies. In keeping with this reputation, Andrew Witty, the chief executive of GlaxoSmithKline has said drug companies should price their products in keeping with the purchase potential in the market reports CNBC-TV18

first published: Sep 27, 2011 09:55 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Follow Us On: Facebook twitter instagram linkedin youtube
News
Business New Market New Stocks Income Tax Calculator Election Schedule 2024 India News Economy Mutual Funds Personal Finance IPO News Startups New USA Elections New
Features
Gold Rate Today Silver Rate Today Trending News Startups New National News MC Videos MC You Tube
Tools
SIP Calculator 2 SIP Calculator 3 SIP Calculator 1 New SIP Calculator 4
Specials
PowerYourTrade Master Your Money Game Changers
Network 18 Sites
News18 Firstpost CNN News18 CNBC TV18 Forbes History TV18
Personal Finance
Home Loans up to 50 Lakhs Credit Cards Lifetime Free Finance Tracker Fixed Deposits Fixed Deposit Comparison Fixed Income Account Aggregator
Quick Links
About Us New Contact Us Advisory Alert New Advertise with Us New Disclaimer Privacy Policy Cookie Policy Terms & Conditions Careers Financial Terms (Glossary) Analytical & Information Tool New
Download MC Apps:

Copyright © Network18 Media & Investments Limited. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.